ライフサイエンスコーパス: radical cystectomy

1 nt strategies particularly as they relate to radical cystectomy.

2 for management of muscle invasive disease is radical cystectomy.

3 rm oncologic outcomes compare well with open radical cystectomy.

4 rapy who were unable or unwilling to undergo radical cystectomy.

5 invasive disease continues to be managed by radical cystectomy.

6 ribing initial experiences with laparoscopic radical cystectomy.

7 ict the 5-year disease recurrence risk after radical cystectomy.

8 l volumes are markers of improved outcome of radical cystectomy.

9 can be determined before, during, and after radical cystectomy.

10 dvanced bladder cancer who were treated with radical cystectomy.

11 been shown to correlate with survival after radical cystectomy.

12 muscle-invasive bladder cancer who received radical cystectomy.

13 n-based combination chemotherapy followed by radical cystectomy.

14 dvanced bladder cancer who were treated with radical cystectomy.

15 tine, doxorubicin, and cisplatin followed by radical cystectomy.

16 stage T2 to T4a) and were to be treated with radical cystectomy.

17 resection bladder tumor, most still require radical cystectomy.

18 of the bladder from patients that underwent radical cystectomy.

19 invasive carcinoma of the urinary bladder is radical cystectomy.

20 5 had a partial cystectomy, and 17 elected a radical cystectomy.

21 to determine the stage of the disease before radical cystectomy.

22 ctomy or progressive disease or death before radical cystectomy.

23 Of these 2 patients, one required radical cystectomy.

24 G therapy and refused or were ineligible for radical cystectomy.

25 n muscle-invasive urothelial carcinoma after radical cystectomy.

26 followed by concurrent chemoradiation) with radical cystectomy.

27 went pre- and postimmunotherapy mpMRI before radical cystectomy.

28 r patients who decline or are ineligible for radical cystectomy.

29 r cancer who were ineligible for or declined radical cystectomy.

30 h muscle-invasive bladder cancer planned for radical cystectomy.

31 treatment and who are ineligible for/refuse radical cystectomy.

32 les of ddMVAC were administered, followed by radical cystectomy.

33 e care and counseling of patients undergoing radical cystectomy.

34 ave been utilized to measure HRQOL following radical cystectomy.

35 er is an important outcome measure following radical cystectomy.

36 catheterizable urinary reservoirs following radical cystectomy.

37 ent of pelvic lymphadenectomy at the time of radical cystectomy.

38 nce supporting the use of minimally invasive radical cystectomy.

39 eed for curative therapeutic alternatives to radical cystectomy.

40 MIBC patients who underwent NAC, followed by radical cystectomy.

41 propriate timing of intravesical therapy and radical cystectomy.

42 ill sustain a complication within 90 days of radical cystectomy.

43 at RARC is an acceptable alternative to open radical cystectomy.

44 s an emerging minimally invasive approach to radical cystectomy.

45 ions and abstracts related to robot-assisted radical cystectomy.

46 guide the scientific practice of LND during radical cystectomy.

47 as improved convalescence compared with open-radical cystectomy.

48 toperative complications with robot-assisted radical cystectomy.

49 erm oncologic outcomes as compared with open radical cystectomy.

50 provided a retrospective comparison to open radical cystectomy.

51 reproducible, minimally invasive approach to radical cystectomy.

52 ances and outcomes related to robot-assisted radical cystectomy.

53 could be spared the unnecessary morbidity of radical cystectomy.

54 ay help in making treatment decisions before radical cystectomy.

55 ssary, can achieve survival rates similar to radical cystectomy.

56 treatment with neoadjuvant chemotherapy and (radical) cystectomy.

57 Of the 17 patients who had radical cystectomy, 11 (65%) are alive.

58 lial carcinoma of the bladder (440 underwent radical cystectomy, 282 received trimodality therapy) wh

59 matched cohort comprised 1119 patients (837 radical cystectomy, 282 trimodality therapy).

60 mproved our understanding of HRQOL following radical cystectomy, a lack of prospective studies limits

61 , liver, pancreas, gynecologic oncology, and radical cystectomy) across 9 sites.

62 eoadjuvant gemcitabine-cisplatin followed by radical cystectomy alone (comparison group).

63 sputed benefit of adjuvant chemotherapy over radical cystectomy alone for muscle-invasive bladder can

64 In cisplatin-ineligible patients, radical cystectomy alone is recommended.

65 nsive disease) and were randomly assigned to radical cystectomy alone or three cycles of methotrexate

66 As compared with radical cystectomy alone, the use of neoadjuvant methotr

67 ated favorable clinical outcomes relative to radical cystectomy alone.

68 radual growth and experience in laparoscopic radical cystectomy, along with continuing refinements in

69 care is neoadjuvant chemotherapy followed by radical cystectomy, an approach that could result in sig

70 sis-free survival was 74% (95% CI 70-78) for radical cystectomy and 75% (70-80) for trimodality thera

71 n every 3 weeks for four cycles, followed by radical cystectomy and adjuvant durvalumab every 4 weeks

72 re was no evidence of an interaction between radical cystectomy and age, sex, comorbidity score, or c

73 immediate versus deferred chemotherapy after radical cystectomy and bilateral lymphadenectomy for pat

74 oncological outcomes of patients treated by radical cystectomy and bilateral lymphadenectomy for uro

75 se or node positive (pN1-3) M0 disease after radical cystectomy and bilateral lymphadenectomy, with n

76 techniques has prompted interest in robotic radical cystectomy and extended PLND, and recent reports

77 rioperative morbidity following contemporary radical cystectomy and identify preoperative, intraopera

78 We assessed whether radical cystectomy and intestinal urinary diversion are

79 omized comparison between minimally invasive radical cystectomy and open radical cystectomy is needed

80 inblastine, doxorubicin, and cisplatin) plus radical cystectomy and pelvic lymph node dissection.

81 Radical cystectomy and pelvic lymphadenectomy (PLND) rem

82 ce, minimally invasive techniques to perform radical cystectomy and PLND have been adopted.

83 r cancer consisting of patients treated with radical cystectomy and PLND.

84 We evaluated the association between radical cystectomy and risk of fracture at any site, con

85 r cancer who declined or were ineligible for radical cystectomy and should be considered a a clinical

86 linical outcomes between patients undergoing radical cystectomy and TMT.

87 showing similar oncological outcomes between radical cystectomy and trimodality therapy for select pa

88 Outcomes for radical cystectomy and trimodality therapy were not stat

89 ; PSM: SHR 0.88 [0.67-1.16]; p=0.37) between radical cystectomy and trimodality therapy.

90 d recovery protocols for patients undergoing radical cystectomy and urinary diversion and describe ou

91 Patients with bladder cancer who have radical cystectomy and urinary diversion are at increase

92 ate (radical prostatectomy), bladder cancer (radical cystectomy and urinary diversion for muscle inva

93 Radical cystectomy and urinary diversion may cause chron

94 vasive disease, more aggressive therapy with radical cystectomy and urinary diversion or trimodal the

95 th muscle-invasive bladder cancer undergoing radical cystectomy and was associated with higher periop

96 nce status of 0-1, were scheduled to undergo radical cystectomy, and were deemed ineligible for or de

97 n cystectomy are lacking, minimally invasive radical cystectomy appears to have superior perioperativ

98 dical prostatectomy and reconstruction after radical cystectomy are discussed.

99 long-term outcomes after minimally invasive radical cystectomy are limited, intermediate term oncolo

100 rospective, randomized comparisons with open radical cystectomy are needed as this technique continue

101 , randomized prospective comparisons to open radical cystectomy are needed to further validate this p

102 for the extirpative portion of laparoscopic radical cystectomy at multiple institutions.

103 rtial nephrectomy, radical prostatectomy, or radical cystectomy between the first quarter (Q1) of 201

104 Morbidity is common following radical cystectomy, but careful attention to preoperativ

105 el function in those undergoing laparoscopic radical cystectomy, but these observations have not been

106 ithin the last year, numerous robot-assisted radical cystectomy case series with larger cohorts have

107 While radical cystectomy cures many patients with this tumor,

108 Institutional radical cystectomy databases containing detailed informa

109 randomized trial comparing open and robotic radical cystectomy demonstrated equivalent lymph node yi

110 timately affect treatment as feasibility for radical cystectomy depends on staging by a combination o

111 tial nephrectomy, radical prostatectomy, and radical cystectomy during the COVID-19 pandemic.

112 , CMT can be considered as an alternative to radical cystectomy, especially in elderly patients not w

113 ients with lymph node-positive disease after radical cystectomy, even in the context of adjuvant chem

114 derwent bilateral pelvic lymphadenectomy and radical cystectomy for bladder cancer (median follow-up,

115 utDNA MRD detection prior to curative-intent radical cystectomy for bladder cancer correlated signifi

116 All patients who underwent radical cystectomy for bladder cancer in any hospital be

117 th-related quality of life (HRQOL) following radical cystectomy for bladder cancer is an important ou

118 Minimally invasive radical cystectomy for bladder cancer is performed lapar

119 rongly suggests that all patients undergoing radical cystectomy for bladder cancer should undergo con

120 er nomogram predicting recurrence risk after radical cystectomy for bladder cancer.

121 surgery improves recovery compared with open radical cystectomy for bladder cancer.

122 orodeoxyglucose (FDG) in patients undergoing radical cystectomy for cT2-3N0M0 urothelial carcinoma of

123 RREB1 expression and overall survival after radical cystectomy for invasive bladder cancer.

124 d trials comparing bladder preservation with radical cystectomy for muscle-invasive bladder cancer cl

125 apy is an effective potential alternative to radical cystectomy for recurrent high-grade T1 urothelia

126 as a minimally invasive alternative to open radical cystectomy for the treatment of bladder cancer.

127 y therapy can be an effective alternative to radical cystectomy for treatment of muscle-invasive blad

128 November 2020 on the day of curative-intent radical cystectomy from 42 patients with localized bladd

129 Robot-assisted radical cystectomy had a much higher probability of bein

130 mph node dissection performed at the time of radical cystectomy has an ability to improve locoregiona

131 d therapeutic role of lymphadenectomy during radical cystectomy has become apparent and recent work h

132 However, the risk of fractures after radical cystectomy has not been defined.

133 ew effective salvage therapy options besides radical cystectomy, highlighting a need for new therapie

134 Perioperative outcomes are as good as open radical cystectomy if not better.

135 mour (TURBT) was performed in 47 (78.4%) and radical cystectomy in 13 (21.6%) patients.

136 inning to emerge and appears similar to open-radical cystectomy in nonrandomized comparisons.

137 splatin-based combination chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 uro

138 tine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminati

139 h there are limited data on robotic assisted radical cystectomy, initial reports suggest that an appr

140 to 6 months to recover baseline levels after radical cystectomy irrespective of surgical approach.

141 Pelvic lymph node dissection at the time of radical cystectomy is a crucial component of the surgica

142 Radical cystectomy is a morbid procedure with rather lon

143 Robot-assisted radical cystectomy is a reproducible, minimally invasive

144 Robot-assisted radical cystectomy is an emerging minimally invasive app

145 rapy fails in >50% of cases, and second-line radical cystectomy is associated with overtreatment and

146 Laparoscopic radical cystectomy is being increasingly performed at se

147 Robot-assisted radical cystectomy is being more widely studied as a pot

148 Robot-assisted radical cystectomy is being performed with increasing fr

149 nimally invasive radical cystectomy and open radical cystectomy is needed to define the role of these

150 nuing refinements in technique, laparoscopic radical cystectomy is now being performed at many center

151 Robot-assisted radical cystectomy is steadily growing with a feasible l

152 The prevalence of robot-assisted radical cystectomy is steadily increasing.

153 Minimally invasive radical cystectomy is technically feasible.

154 inum-based neoadjuvant chemotherapy prior to radical cystectomy is the preferred treatment for muscle

155 Radical cystectomy is the standard of care for patients

156 Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplat

157 ed muscle-invasive bladder cancer undergoing radical cystectomy is unclear.

158 008, and it is superseding pure laparoscopic radical cystectomy (LRC) at centers, where robot is avai

159 Radical cystectomy may include resection of adjacent org

160 g 338 randomized participants, 317 underwent radical cystectomy (mean age, 69 years; 67 women [21%];

161 e oncological efficacy of minimally invasive radical cystectomy (MIRC) and PLND.

162 racorporeal reconstruction (n = 169) or open radical cystectomy (n = 169).

163 ed measures of functional independence after radical cystectomy (open or robotic).

164 mary tumor burden, defined as the receipt of radical cystectomy or >/= 50 Gy of radiation therapy del

165 bladder cancer, 151 were treated by standard radical cystectomy or by definitive TUR, if restaging TU

166 1, or 2 were enrolled within 14 weeks after radical cystectomy or nephroureterectomy with lymph node

167 Robot-assisted radical cystectomy or open radical cystectomy (ORC).

168 able set was defined as all patients who had radical cystectomy or progressive disease or death befor

169 al therapy of his primary bladder tumor with radical cystectomy or radiation.

170 statectomy (OR, 0.85; 95% CI, 0.22-3.22), or radical cystectomy (OR, 0.69; 95% CI, 0.31-1.53) was unc

171 for progression, recurrence, not undergoing radical cystectomy, or death from any cause, 0.68; 95% C

172 Open radical cystectomy (ORC) and pelvic lymph node dissectio

173 ry diversion (iRARC) when compared with open radical cystectomy (ORC) for patients with bladder cance

174 Robot-assisted radical cystectomy or open radical cystectomy (ORC).

175 Although the added benefits of radical cystectomy over simple cystectomy alone are acce

176 ladder cancer outcome in patients undergoing radical cystectomy, p53 is the strongest predictor, foll

177 tic aneurysm repair, carotid endarterectomy, radical cystectomy, pancreatic resection, and esophagect

178 Pathological stage in the 440 radical cystectomy patients was pT2 in 124 (28%), pT3-4

179 s of radical cystectomy represent 29% of all radical cystectomies performed during the study period a

180 er of altered markers in patients treated by radical cystectomy provides prognostic information that

181 tients undergoing open or minimally invasive radical cystectomy, radical or partial nephrectomy, and

182 l principles for technique of robot-assisted radical cystectomy (RARC) based on current peer reviewed

183 Robot-assisted radical cystectomy (RARC) continues to provide a minimal

184 cal community has put hope in robot-assisted radical cystectomy (RARC) with intracorporeal urinary di

185 opments and current status of robot-assisted radical cystectomy (RARC) with pelvic lymphadenectomy (P

186 trimodal therapy (TMT) is an alternative to radical cystectomy (RC) according to international guide

187 Although radical cystectomy (RC) currently is viewed as the stand

188 erapy (TMT) is included as an alternative to radical cystectomy (RC) for definitive management of mus

189 t gemcitabine and cisplatin (GC) followed by radical cystectomy (RC) is standard for patients with mu

190 ntenance Bacillus Calmette-Guerin (mBCG) and radical cystectomy (RC).

191 undergo neoadjuvant chemotherapy followed by radical cystectomy (RC).

192 urologic cancer-related surgical procedures (radical cystectomy [RC], radical nephrectomy [RN], and r

193 rvations might have implications in terms of radical cystectomy recommendation in MPBC patients.

194 ng-term oncologic outcomes with laparoscopic radical cystectomy remain undefined, and appropriate lym

195 Radical cystectomy remains the gold-standard therapy for

196 .), management guidelines are less clear and radical cystectomy remains the mainstay of treatment at

197 While radical cystectomy remains the mainstay of treatment for

198 The 440 cases of radical cystectomy represent 29% of all radical cystecto

199 Optimal outcomes following radical cystectomy require an extended lymph node dissec

200 ith intracorporeal urinary diversion vs open radical cystectomy resulted in a statistically significa

201 s examined immunohistochemically on archival radical cystectomy samples from 164 patients with invasi

202 s, with rates of overall survival similar to radical cystectomy series.

203 appear to be equivalent to contemporary open radical cystectomy series.

204 nal and oncologic outcome data, laparoscopic radical cystectomy should be considered an investigative

205 tomy, 13 327 radical prostatectomy, and 2270 radical cystectomy surgical procedures were performed.

206 e into alternative treatments, such as early radical cystectomy, targeted therapies, or immunotherapi

207 oncologic outcomes appear comparable to open radical cystectomy, the reference standard.

208 ted for early aggressive intervention (i.e., radical cystectomy), then treatment recommendations shou

209 204) and phospho-Akt (S473), and analysis of radical cystectomy tissues from patients with BlCa showe

210 iew the current experience with laparoscopic radical cystectomy to identify its role in oncological b

211 dequate lymph node dissection at the time of radical cystectomy to optimize oncologic outcomes.

212 with nonmetastatic bladder cancer undergoing radical cystectomy, treatment with robot-assisted radica

213 5-year cancer-specific survival for radical cystectomy versus trimodality therapy was 81% (9

214 atching, age (71.4 years [IQR 66.0-77.1] for radical cystectomy vs 71.6 years [64.0-78.9] for trimoda

215 Robot-assisted radical cystectomy was associated with statistically sig

216 Radical cystectomy was performed in 88.0% of the patient

217 residual disease (higher than stage ypT0) at radical cystectomy were 67%-84%, 63%-96%, and 63%-75%, r

218 0-2, and who were ineligible for or declined radical cystectomy were enrolled.

219 FGFR alterations refusing or ineligible for radical cystectomy were randomized to 6 mg daily oral er

220 for muscle-invasive bladder cancer (MIBC) is radical cystectomy, which is typically preceded by neoad

221 muscle-invasive bladder cancer scheduled for radical cystectomy who are ineligible for or decline to

222 Radical cystectomy with an appropriate lymph node dissec

223 All patients undergoing radical cystectomy with bilateral pelvic iliac lymphaden

224 Radical cystectomy with bilateral pelvic lymph node diss

225 sive disease in the United States centers on radical cystectomy with bilateral pelvic lymphadenectomy

226 Laparoscopic radical cystectomy with extended lymphadenectomy provide

227 findings regarding the clinical benefits of radical cystectomy with extended lymphadenectomy, and wi

228 verall survival rates in patients undergoing radical cystectomy with extended PLND, even in cases of

229 ts were randomized to receive robot-assisted radical cystectomy with intracorporeal reconstruction (n

230 al cystectomy, treatment with robot-assisted radical cystectomy with intracorporeal urinary diversion

231 The value to payers of robot-assisted radical cystectomy with intracorporeal urinary diversion

232 cles of AMVAC with pegfilgrastim followed by radical cystectomy with lymph node dissection.

233 For muscle-invasive bladder cancer, radical cystectomy with neoadjuvant chemotherapy is the

234 adder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers

235 Radical cystectomy with pelvic lymph node dissection (PL

236 n-based neoadjuvant chemotherapy followed by radical cystectomy with pelvic lymph node dissection, wh

237 assess the current status of robot-assisted radical cystectomy with pelvic lymphadenectomy and urina

238 Radical cystectomy with perioperative systemic therapy,

239 disease occurs, then patients must undergo a radical cystectomy with risks of substantial morbidity a

240 Radical cystectomy with thorough pelvic lymphadenectomy

241 Robot-assisted radical cystectomy with urinary diversion appears to be

242 Standard of care in these patients is radical cystectomy with urinary diversion, but this appr

243 en neoadjuvant chemotherapy followed by open radical cystectomy with urinary diversion.